The 75 RS Rating means that Translate Bio stock has outperformed 75% of all stocks, regardless of industry group, over the past year.
Translate Bio stock Near Key Price Threshold.
Stocks that go on to make the biggest gains typically have an RS Rating of at least 80 as they launch their largest runs. See if small-cap Translate Bio can continue to show renewed price strength and clear that threshold.
Translate Bio develops treatments for diseases caused by protein or gene dysfunction.
In mid-March 2020, Translate Bio stock bottomed at 6.80 a share amid the coronavirus crash. It was trading at 22.80 Monday afternoon, down fractionally for the day but up about 235% in the last 15 months.
Earnings for the Lexington, Mass.-based company soared 241% in the company’s most recent quarterly report, to 34 cents per share. Sales climbed 644% to $34.6 million, the latest in a string of at least four quarters of triple-digit year-over-year revenue growth.
Translate Bio holds the No. 41 rank among its peers in the Medical-Biomed/Biotech industry group. Maravai LifeSciences (MRVI) and Vanda Pharmaceuticals (VNDA) are among the group’s highest-rated stocks.
Translate Bio stock is well above its 50-day and 200-day lines, but not currently near a potential buying area. See if the stock goes on to form a promising consolidation that could launch a new move.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating tracks market leadership by showing how a stock’s price movement over the last 52 weeks measures up against that of the other stocks in our database.
YOU MIGHT ALSO LIKE: